Organon & Co. Common Stock vs QUALCOMM, Inc. — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while QUALCOMM, Inc. trades at $171.32 (market cap $188.86B). The key difference: QUALCOMM, Inc. is far larger — about 52.2× Organon & Co. Common Stock's market cap, and QUALCOMM, Inc. pays the higher dividend (2.08%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and QUALCOMM, Inc. for 87 Days on average.
| OGN | QCOM | |
|---|---|---|
Market Cap | $3.62B | $188.86B |
Volume | 2,892,999 | 12,280,716 |
Sector | Health | Technology |
52-Week High | $13.81 | $251.10 |
52-Week Low | $5.70 | $124.07 |
Typical Hold Time | 0 Days | 87 Days |
Enterprise Value | $11.04B | $195.82B |
Dividend Yield | 0.58% | 2.08% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Qualcomm (QCOM) trades at $174.43, down 0.61% today, with a bearish technical signal despite recent AI-driven optimism. The company reported mixed Q2 2026 earnings, missing EPS estimates at $2.21 versus $2.23 expected, but maintains strong profitability with 54.23% gross margins and 21.01% net income margin. Recent news highlights a transformative $60 billion Amazon AI partnership, boosting data center ambitions beyond its core handset business.
QCOM's valuation appears reasonable with a P/E of 20.21, trading below the analyst consensus price target of $204.48. Key opportunities include AI data center growth and automotive expansion, while risks involve smartphone dependency and competitive pressures. Wall Street sentiment is mixed with 43.48% buy ratings, but the stock offers potential upside if AI bets materialize.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →